(0.81%) 5 123.50 points
(0.13%) 38 337 points
(1.10%) 17 761 points
(0.38%) $83.89
(-3.36%) $1.583
(0.23%) $2 348.00
(0.85%) $27.59
(1.10%) $930.60
(0.09%) $0.933
(0.13%) $10.97
(0.07%) $0.800
(0.01%) $92.18
@ $19.52
Išleistas: 14 vas. 2024 @ 21:28
Grąža: -19.34%
Ankstesnis signalas: vas. 14 - 18:53
Ankstesnis signalas:
Grąža: 2.55 %
Live Chart Being Loaded With Signals
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong...
Stats | |
---|---|
Šios dienos apimtis | 515 424 |
Vidutinė apimtis | 645 011 |
Rinkos kapitalizacija | 1.55B |
EPS | $0 ( 2024-02-27 ) |
Kita pelno data | ( $-0.930 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.50 |
ATR14 | $0.0210 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Smiley Joshua L | Buy | 7 145 | American Depositary Shares |
2024-04-04 | Smiley Joshua L | Sell | 1 988 | American Depositary Shares |
2024-04-03 | Smiley Joshua L | Sell | 7 145 | Restricted Share Units |
2024-04-03 | Reinhart Harald | Buy | 5 270 | American Depositary Shares |
2024-04-04 | Reinhart Harald | Sell | 2 105 | American Depositary Shares |
INSIDER POWER |
---|
72.37 |
Last 100 transactions |
Buy: 2 027 943 | Sell: 363 897 |
Tūris Koreliacija
Zai Lab Ltd Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MMAC | 0.88 |
NETE | 0.872 |
BOCH | 0.84 |
TFSL | 0.832 |
SHSP | 0.828 |
SNFCA | 0.824 |
LWAC | 0.815 |
DOOO | 0.809 |
CLGN | 0.804 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
RMRM | -0.867 |
SVAC | -0.866 |
PAIC | -0.846 |
SVOK | -0.828 |
GAINL | -0.815 |
TLGT | -0.81 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Zai Lab Ltd Koreliacija - Valiuta/Žaliavos
Zai Lab Ltd Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $266.72M |
Bruto pelnas: | $170.90M (64.08 %) |
EPS: | $-3.46 |
Q4 | 2023 |
Pajamos: | $65.83M |
Bruto pelnas: | $40.59M (61.66 %) |
EPS: | $-0.980 |
Q3 | 2023 |
Pajamos: | $69.23M |
Bruto pelnas: | $43.75M (63.20 %) |
EPS: | $-0.710 |
Q2 | 2023 |
Pajamos: | $68.86M |
Bruto pelnas: | $45.10M (65.49 %) |
EPS: | $-1.250 |
Financial Reports:
No articles found.
Zai Lab Ltd
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.